S

Seattle Cancer Care Alliance | Division of Medical Oncology - Hematologic Malignancies - UW Medicine

Research site
(Unclaimed)
Location
825 Eastlake Avenue E, CE3-300, Seattle, Washington, United States of America

Site insights

Top conditions

Top treatments

Fludarabine
Cyclophosphamide
Dexamethasone
PDR001
Bortezomib
Cisplatin
Bevacizumab
Gemcitabine
Thiotepa
Nivolumab

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

14 of 90 total trials

A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)

A Phase 1 Open-label, Multi-center Study of the Safety, Pharmacokinetics (PK), and Anti-tumor Activity of LYT- 200 in Patients with Relapsed/Refracto...

Enrolling
MDS
AML, Adult Recurrent
Drug: Decitabine
Drug: LYT-200
Locations recently updated

The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP)...

Enrolling
Relapsed or Refractory Multiple Myeloma
Drug: Talquetamab
Drug: Dexamethasone

The main purpose of this study is to measure how well abemaciclib works in participants with early breast cancer who are taking hormone therapy after...

Active, not recruiting
Breast Neoplasms
Drug: Placebo
Drug: Abemaciclib

The purpose of this study is to assess the safety and effectiveness of nivolumab with docetaxel in men with advanced castration resistant prostate ca...

Active, not recruiting
Prostate Cancer
Biological: Nivolumab
Other: Placebo

This is an open-label, multi-center Phase 1/2 study of oral LOXO-305 (pirtobrutinib) in patients with CLL/SLL and NHL who have failed or are intolera...

Active, not recruiting
Waldenstrom Macroglobulinemia
Marginal Zone Lymphoma
Drug: Venetoclax
Drug: Rituximab

The purpose of this study is to assess the safety profile of relatlimab plus nivolumab in combination with platinum doublet chemotherapy (PDCT) and t...

Active, not recruiting
Metastatic Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
Drug: Nab-Paclitaxel
Drug: Cisplatin
Locations recently updated

The purpose of this study is to evaluate the efficacy and safety of daratumumab plus cyclophosphamide, bortezomib and dexamethasone (CyBorD) compared...

Active, not recruiting
Amyloidosis
Drug: Daratumumab
Drug: Cyclophosphamide

This randomized phase III trial studies how well avelumab works in treating patients with Merkel cell cancer that has spread to the lymph nodes and h...

Active, not recruiting
Stage IIIB Merkel Cell Carcinoma AJCC v8
Stage III Merkel Cell Carcinoma AJCC v8
Other: Placebo
Other: Peripheral Blood Collection

This is a multicenter, open-label, extension study to evaluate the long-term safety, tolerability, and efficacy of treatment with AG-348 in participa...

Active, not recruiting
Pyruvate Kinase Deficiency
Drug: AG-348

This is a randomized study to compare the efficacy and safety of zanubrutinib plus rituximab versus bendamustine plus rituximab in previously untreat...

Active, not recruiting
Mantle Cell Lymphoma; Non-Hodgkin Lymphoma
Drug: zanubrutinib
Drug: bendamustine

This is a study of the efficacy, pharmacokinetics, and safety of DS-1062a in participants with advanced or metastatic non-small cell lung cancer (NSC...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: DS-1062a

The purpose of this study is to evaluate the efficacy and safety of NIS793 in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-pacl...

Active, not recruiting
Metastatic Pancreatic Ductal Adenocarcinoma
Drug: Nab-paclitaxel
Drug: Gemcitabine

This study is a Phase 2/3 prospective, double-blind, randomized, multi-center, placebo-controlled study for prevention of acute GVHD (aGVHD) in subje...

Enrolling
Acute-graft-versus-host Disease
Biological: Alpha-1 antitrypsin (AAT)
Biological: Placebo

A 10 week trial to assess the ability of Tempol to prevent and/or reduce toxicities associated with cisplatin and radiation treatment in head and nec...

Enrolling
Nephrotoxicity
Ototoxicity
Drug: Tempol
Drug: Placebo Solution

Trial sponsors

Fred Hutchinson Cancer Center (FHCC) logo
Novartis logo
University of Washington logo
Bristol-Myers Squibb (BMS) logo
D
Gilead Sciences logo
Pfizer logo
National Cancer Institute (NCI) logo
Celgene logo
I

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems